Claim card

Packet gate before anyone calls a simulation a Phase II

Six fields. No agency opinion.

Is this packet a Phase II decision?

Reuters reported on 27 October 2026 that Swiss start-up Atlast Bio raised $12.5 million, led by Creandum, to run drug trials on virtual patients. This desk does not run those trials. It asks whether a packet is even shaped like a Phase II decision, and it refuses a simulation even when every field is filled.

Review a packet

Programme licence

USD 100,000 a year, one clinical-development group.

The signer is a head of biostatistics or a VP of clinical development who is being asked to treat a model as the Phase II. The licence is the private gate and four packet reviews. This page does not take a card.

Ask for a packet review